SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma

被引：64

作者：

Jin, Guang-Zhi ^{[1
]}

Yu, Wen-Long ^{[2
]}

Dong, Hui ^{[1
]}

Zhou, Wei-Ping ^{[3
]}

Gu, Yi-Jin ^{[1
]}

Yu, Hao ^{[6
]}

Yu, Hua ^{[1
]}

Lu, Xin Yuan ^{[1
]}

Xian, Zhi-Hong ^{[1
]}

Liu, Yin-Kun ^{[4
,5
]}

Cong, Wen-Ming ^{[1
]}

Wu, Meng-Chao ^{[7
]}

机构：

[1] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai 200438, Peoples R China

[2] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Billiary Tract Surg 2, Shanghai 200438, Peoples R China

[3] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Dept Hepat Surg 3, Shanghai 200438, Peoples R China

[4] Fudan Univ, Liver Canc Inst, Zhong Shan Hosp, Shanghai 200032, Peoples R China

[5] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China

[6] Second Mil Med Univ, Dept Laparoscopy, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China

[7] Second Mil Med Univ, Dept Surg, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2013年 / 59卷 / 03期

基金：

中国国家自然科学基金;

关键词：

High grade dysplastic nodules; Well-differentiated small hepatocellular carcinoma; Sulfite oxidase; Aldo-keto reductase family 1 member B10; CD34; Diagnosis; Prognosis; DYSPLASTIC NODULES; CD34; IMMUNOHISTOCHEMISTRY; SULFITE OXIDASE; LIVER; CIRRHOSIS; BENIGN; IDENTIFICATION; CLASSIFICATION; DEFICIENCY; GLYPICAN-3;

D O I：

10.1016/j.jhep.2013.04.028

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background & Aims: To investigate diagnostic and prognostic values of sulfite oxidase (SUOX) in patients with hepatocellular carcinoma (HCC) who underwent curative resection. Methods: We investigated immunohistochemically the expression dynamics of SUOX, aldo-ketoreductase family 1 member B10 (AKR1B10) and CD34 at different stages of HCC. The differential diagnostic performance of three markers or their combinations in high-grade dysplastic nodules (HGDNs) and well-differentiated small HCC (WD-sHCC) were investigated by logistic regression models and validated in an independent testing set. Overall survival (OS) and time to recurrence (TTR) were evaluated in 300 patients with HCC as the testing cohort, and validated in 198 patients with HCC. Results: SUOX was decreased and AKR1B10 and CD34 were increased with the stepwise progression of hepatocarcinogenesis. For differential diagnosis of WD-sHCC from HGDNs, the sensitivity and specificity of the SUOX + AKR1B10 + CD34 combination for WD-sHCC detection were 93.8% and 95.2%, respectively, and overall accuracy was much higher than any of the three individual markers and two marker combinations. In addition, SUOX, but not AKR1B10 and CD34, was an independent prognostic factor for OS and TTR, and showed better correlation with OS and TTR if combined with serum a-fetoprotein (AFP) for both the testing and validation cohorts. Conclusions: SUOX + AKR1B10 + CD34 combination could make a substantial contribution to hepatic immunopathological diagnosis to distinguish WD-sHCC from HGDNs. Meanwhile, SUOX combined with serum AFP may predict postoperative outcome and tumor recurrence risk. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B. V. All rights reserved.

引用

页码：510 / 517

页数：8

共 29 条

[21] Preneoplastic lesions in human hepatocarcinogenesis [J].